This disclosure relates generally to medical devices, and more specifically, to medical devices for connecting tissue layers to create an anastomosis, implantable devices for occluding inhibiting or preventing material movement through tissue apertures, sealing, and allowing healing of defects in tissues, and deployment of the medical devices discussed herein.
An anastomosis is a cross-connection between two tissue structures, such as blood vessels or intestines. For example, in the context of coronary artery bypass graft surgery, a graft vessel is anastomosed to a native coronary artery so that blood can flow through the graft vessel.
Anastomoses can be created in various manners including, but not limited to: end-to-end, end-to-side, and side-to-side anastomoses. Often, suturing is used to create such anastomoses.
Various aspects of the present disclosure are directed toward medical device systems. The medical device systems may include an expandable medical device having a first end portion, a second end portion, and an intermediate portion between the first end portion and the second end portion. The intermediate portion of the expandable medical device may include a radially expansive force greater than a radially expansive force of at least one of the first end portion and the second end portion. In addition, the expandable medical device may include a first constraining mechanism configured to releasably constrain the expandable medical device, and a second constraining mechanism arranged between the expandable medical device and the first constraining mechanism and configured to lessen expansion of the intermediate portion of the expandable medical device in response to release of the first constraining mechanism.
Various aspects of the present disclosure are also directed toward systems for deploying a medical device having a first flange, a second flange, and an intermediate portion therebetween and a delivery configuration and a deployed configuration. The systems include a first constraining mechanism configured to constrain the expandable medical device to the delivery configuration and deploy the first flange and the second flange to the deployed configuration in response to release thereof, and a second constraining mechanism arranged between the expandable medical device and the first constraining mechanism and configured to maintain the intermediate portion of the expandable medical device in an intermediate configuration in response to release of the first constraining mechanism.
Aspects of the disclosure are also directed toward methods of deploying an expandable medical device having a delivery configuration and a deployed configuration. The methods include positioning the expandable medical device at the target location (with expandable medical device including a first end portion, a second end portion, and an intermediate portion having a radially expansive force greater than a radially expansive force of the first end portion). The methods also include releasing a first constraining mechanism to deploy the first end portion and the second end portion to the deployed configuration and deploy the intermediate portion to an intermediate configuration. Further, the methods include releasing a second constraining mechanism to deploy the intermediate portion to the deployed configuration.
According to one example (“Example 1”), a medical device system includes an expandable medical device including a first end portion, a second end portion, and an intermediate portion therebetween, the intermediate portion having a radially expansive force greater than a radially expansive force of at least one of the first end portion and the second end portion; a first constraining mechanism configured to releasably constrain the expandable medical device; and a second constraining mechanism arranged between the expandable medical device and the first constraining mechanism and configured to lessen expansion of the intermediate portion of the expandable medical device in response to release of the first constraining mechanism.
According to another example (“Example 2”) further to Example 1, the first constraining mechanism and the second constraining mechanism are configured to deploy the intermediate portion of the expandable medical device to an intermediate configuration and deploy the first end portion and the second end portion of the expandable medical device to a deployed configuration in response to release of the first constraining mechanism.
According to another example (“Example 3”) further to Example 2, the second constraining mechanism is configured to release and deploy the intermediate portion of the expandable medical device to the deployed configuration.
According to another example (“Example 4”) further to Example 3, the second constraining mechanism is configured to release in response to a force applied thereto.
According to another example (“Example 5”) further to Example 4, the force is a radial force applied within the intermediate portion of the expandable medical device, and the second constraining mechanism is configured to remain coupled to the expandable medical device subsequent to the force being applied thereto.
According to another example (“Example 6”) further to Example 1, the first end portion includes a first flange, the second end portion includes a second flange, and the intermediate portion includes a substantially cylindrical shape.
According to another example (“Example 7”) further to Example 6, the expandable medical device includes a first inflection area between the first flange and the intermediate portion, a second inflection area between the second flange and the intermediate portion, and the second constraining mechanism is arranged between the first inflection area and the second inflection area.
According to another example (“Example 8”) further to Example 1, the second constraining mechanism is coupled to the expandable medical device, and the first constraining mechanism is configured to deploy the expandable medical device and uncouple from the expandable medical device in response to tension applied to the first constraining mechanism.
According to another example (“Example 9”) further to Example 1, the first constraining mechanism is configured to releasably constrain the expandable medical device to a substantially cylindrical delivery configuration.
According to another example (“Example 10”) further to Example 9, the first constraining mechanism extends from a proximal end of the expandable medical device to a distal end of the expandable medical device and back toward a proximal end of the expandable medical device.
According to one example (“Example 11”) a system for deploying a medical device having a first flange, a second flange, and an intermediate portion therebetween, a delivery configuration, and a deployed configuration. In Example 11, the system includes: a first constraining mechanism configured to constrain the medical device to the delivery configuration and deploy the first flange and the second flange to the deployed configuration in response to release of the first constraining mechanism; and a second constraining mechanism arranged between the medical device and the first constraining mechanism and configured to maintain the intermediate portion of the medical device in an intermediate configuration in response to release of the first constraining mechanism.
According to another example (“Example 12”) further to Example 11, the intermediate portion includes a radially expansive force greater than a radially expansive force of at least one of the first flange and the second flange.
According to another example (“Example 13”) further to Example 11, the second constraining mechanism is coupled to the medical device and secured to the intermediate portion.
According to another example (“Example 14”) further to Example 11, the second constraining mechanism is arranged about a circumference of the intermediate portion of the medical device.
According to another example (“Example 15”) further to Example 11, a diameter of the intermediate portion in the intermediate configuration is approximately between 40% to 80% less than a diameter of the intermediate portion in the deployed configuration.
According to another example (“Example 16”) further to Example 11, the first constraining mechanism is configured to deploy the medical device and uncouple from the medical device in response to release of the first constraining mechanism.
According to one example (“Example 17”), a method of deploying an expandable medical device having a delivery configuration and a deployed configuration. In Example 17, the method includes positioning the expandable medical device at the target location, the expandable medical device including a first end portion, a second end portion, and an intermediate portion therebetween, the intermediate portion having a radially expansive force greater than a radially expansive force of the first end portion; releasing a first constraining mechanism to deploy the first end portion and the second end portion to the deployed configuration and deploy the intermediate portion to an intermediate configuration; and releasing a second constraining mechanism to deploy the intermediate portion to the deployed configuration.
According to another example (“Example 18”) further to Example 17, releasing the second constraining mechanism includes applying a force to the second constraining mechanism to deploy the intermediate portion to the deployed configuration from the intermediate configuration.
According to another example (“Example 19”) further to Example 17, a diameter of the intermediate portion in the intermediate configuration is approximately between 40% to 80% less than a diameter of the intermediate portion in the deployed configuration.
According to another example (“Example 20”) further to Example 17, releasing the first constraining mechanism includes uncoupling the first constraining mechanism from the expandable medical device, and releasing the second constraining mechanism includes maintaining at least a portion of the second constraining mechanism attached to the intermediate portion of the expandable medical device.
According to one example (“Example 21”) a medical device system includes an expandable medical device including a first end portion, a second end portion, and an intermediate portion therebetween, the intermediate portion having a radially expansive force greater than a radially expansive force of at least one of the first end portion and the second end portion; a first constraining mechanism configured to releasably constrain the expandable medical device; and a second constraining mechanism arranged between the expandable medical device and the first constraining mechanism and configured to lessen expansion of the intermediate portion of the expandable medical device in response to release of the first constraining mechanism.
According to another example (“Example 22”) further to Example 21, the first constraining mechanism and the second constraining mechanism are configured to deploy the intermediate portion of the expandable medical device to an intermediate configuration and deploy the first end portion and the second end portion of the expandable medical device to a deployed configuration in response to release of the first constraining mechanism.
According to another example (“Example 23”) further to any one of Examples 21-22, the second constraining mechanism is configured to release and deploy the intermediate portion of the expandable medical device to the deployed configuration.
According to another example (“Example 24”) further to Example 23, the second constraining mechanism is configured to release in response to a force applied thereto.
According to another example (“Example 25”) further to Example 24, the force is a radial force applied within the intermediate portion of the expandable medical device, and the second constraining mechanism is configured to remain coupled to the expandable medical device subsequent to the force being applied thereto.
According to another example (“Example 26”) further to any one of Examples 21-25, the first end portion includes a first flange, the second end portion includes a second flange, and the intermediate portion includes a substantially cylindrical shape.
According to another example (“Example 27”) further to Example 26, the expandable medical device includes a first inflection area between the first flange and the intermediate portion, a second inflection area between the second flange and the intermediate portion, and the second constraining mechanism is arranged between the first inflection area and the second inflection area.
According to another example (“Example 28”) further to any one of Examples 21-27, the second constraining mechanism is coupled to the expandable medical device, and the first constraining mechanism is configured to deploy the expandable medical device and uncouple from the expandable medical device in response to tension applied to the first constraining mechanism.
According to another example (“Example 29”) further to any one of Examples 21-28, the first constraining mechanism is configured to releasably constrain the expandable medical device to a substantially cylindrical delivery configuration.
According to another example (“Example 30”) further to Example 29, the first constraining mechanism extends from a proximal end of the expandable medical device to a distal end of the expandable medical device and back toward a proximal end of the expandable medical device.
According to one example (“Example 31”), a system for deploying a medical device having a first flange, a second flange, and an intermediate portion therebetween, a delivery configuration, and a deployed configuration with the system including: a first constraining mechanism configured to constrain the medical device to the delivery configuration and deploy the first flange and the second flange to the deployed configuration in response to release of the first constraining mechanism; and a second constraining mechanism arranged between the medical device and the first constraining mechanism and configured to maintain the intermediate portion of the medical device in an intermediate configuration in response to release of the first constraining mechanism.
According to another example (“Example 32”) further to Example 31, the intermediate portion includes a radially expansive force greater than a radially expansive force of at least one of the first flange and the second flange.
According to another example (“Example 33”) further to any one of Examples 31-32, the second constraining mechanism is coupled to the medical device and secured to the intermediate portion.
According to another example (“Example 34”) further to any one of Examples 31-33, the second constraining mechanism is arranged about a circumference of the intermediate portion of the medical device.
According to another example (“Example 35”) further to any one of Examples 31-34, a diameter of the intermediate portion in the intermediate configuration is approximately between 40% to 80% less than a diameter of the intermediate portion in the deployed configuration.
According to another example (“Example 36”) further to any one of Examples 31-35, the first constraining mechanism is configured to deploy the medical device and uncouple from the medical device in response to release of the first constraining mechanism.
According to one example (“Example 37”), a method of deploying an expandable medical device having a delivery configuration and a deployed configuration, the method including: positioning the expandable medical device at the target location, the expandable medical device including a first end portion, a second end portion, and an intermediate portion therebetween, the intermediate portion having a radially expansive force greater than a radially expansive force of the first end portion; releasing a first constraining mechanism to deploy the first end portion and the second end portion to the deployed configuration and deploy the intermediate portion to an intermediate configuration; and releasing a second constraining mechanism to deploy the intermediate portion to the deployed configuration.
According to another example (“Example 38”) further to Example 37, releasing the second constraining mechanism includes applying a force to the second constraining mechanism to deploy the intermediate portion to the deployed configuration from the intermediate configuration.
According to another example (“Example 39”) further to any one of Examples 37-38, a diameter of the intermediate portion in the intermediate configuration is approximately between 40% to 80% less than a diameter of the intermediate portion in the deployed configuration.
According to another example (“Example 40”) further to any one of Examples 37-39, releasing the first constraining mechanism includes uncoupling the first constraining mechanism from the expandable medical device, and releasing the second constraining mechanism includes maintaining at least a portion of the second constraining mechanism attached to the intermediate portion of the expandable medical device.
Persons skilled in the art will readily appreciate that various aspects of the present disclosure can be realized by any number of methods and apparatus configured to perform the intended functions. It should also be noted that the accompanying figures referred to herein are not necessarily drawn to scale, but may be exaggerated to illustrate various aspects of the present disclosure, and in that regard, the figures should not be construed as limiting.
Various aspects of the present disclosure are directed to medical devices for connecting tissue layers, for example, to circumvent a conduit or organ blockage, such as by creating a direct passage between tissue structures to create an anastomosis that facilitates material flow therebetween. The expandable medical devices may be endoscopically deployable or deliverable via a catheter and may be self-expanding to facilitate a secure connection between the tissue structures. The present disclosure discusses one or more constraining mechanisms that facilitate deployment of the expandable medical devices that facilitate delivery thereof and lessen misdeployment.
Such an implementation may provide a beneficial treatment to the patient when, for example, a flow blockage exists in the native anatomical conduits connecting the internal gallbladder space 104 and the internal intestinal space 108. In certain instances the patient may have one or more gallstones that cause a blockage of the patient's cystic duct 110 and/or common bile duct 112. In such a case, the expandable medical device 100 may provide a fluidic passageway such that bile from the gallbladder 102 may flow into the intestine 106.
The expandable medical device 100 may include a first end portion 114, a second end portion 116, and an intermediate portion 118 therebetween. The intermediate portion 118 defines a lumen 120 that extends longitudinally from the first end portion 114 to the second end portion 116. The lumen 120 may act as a connection (e.g., a shunt passageway) between the two spaces (e.g., tissue structures, conduits, organs) that the expandable medical device 100 connects. In the example shown in
Although
To deploy the expandable medical device arranged with the delivery system 200, tension may be applied to a deployment line 206 coupled to the first constraining mechanism 204. The deployment line 206 is accessible to a user such as a physician and may be arranged through a port 208 in the catheter body 202. In response to tension applied to the deployment line 206, the primary constraining mechanism 204 may open, withdraw or evert from an end of the delivery system 200, such as a distal tip 210, toward the port 208. In some embodiments, the first constraining mechanism 204 may have multiple layers constraining the expandable medical device and as such may move from one end of the delivery zone to the other end multiple times during deployment. In certain instances, the delivery system 200 may also include a skirt 212 that is arranged about the first constraining mechanism 204 prior to the delivery system 200 being traversed to a target location within a patient.
To deploy the expandable medical device 300, tension may be applied to a deployment line 312 coupled to the first constraining mechanism 302, which is accessible to a user such as a physician. In response, the first constraining mechanism 302 may open, withdraw or evert from the proximal end 306 towards the distal end 308 and then continue back toward the proximal end 306 of the expandable medical device 300. Releasing the first constraining mechanism 302 in this manner may deploy the distal end 308 of the expandable medical device 300 prior to deploying the remaining portions of the expandable medical device 300.
A second constraining mechanism 304, arranged between the expandable medical device 300 and the first constraining mechanism 302 in the delivery configuration shown in
In certain instances, the intermediate portion 318 is approximately cylindrical whereas the first flange 314 and the second flange 316 deploy approximately perpendicular to the intermediate portion 318 such that the expandable medical device 300 includes an hourglass shape having a lumen therethrough in an intermediate configuration (shown in
To facilitate staged deployment of the expandable medical device 300, the second constraining mechanism 304 may be configured to mitigate against premature expansion of the intermediate portion 318. The expandable medical device 300, in certain instances, is self-expanding and therefore is biased to deploy to the full-deployed configuration from the delivery configuration. In certain instances, the intermediate portion 318 and the first flange 314 and/or the second flange 316 having different radial forces may result in forces from the intermediate portion 318, desiring to be in the deployed configuration, to force the first constraining mechanism 302 from the expandable medical device 300. The second constraining mechanism 304 is configured to lessen expansion of the intermediate portion 318 by deploying the intermediate portion 318 to the intermediate configuration as opposed to directly to the deployed configuration.
The second constraining mechanism 304 is configured to release in response to a force applied thereto. In certain instances, the force is applied from within the intermediate portion 318 of the expandable medical device 300 to break, fracture, or distend the second constraining mechanism 304. In certain instances, the second constraining mechanism 304 remains coupled to the intermediate portion 318 of the expandable medical device 300 after release thereof. The intermediate portion 318 of the expandable medical device 300 may deploy to the fully-deployed configuration, for example, as shown in
In addition, the first end portion 604, the second end portion 606, and the intermediate portion 608 are formed by a framework of elongate elements 610. As shown in
In addition and in certain instances, the intermediate portion 608 includes a radially expansive force greater than a radially expansive force than one or both of the first end portion 604 and the second end portion 606 in the delivery (constrained) configuration. The expandable medical device 600 is deployed by releasing a first constraining mechanism (e.g., as shown in
In addition to deploying the intermediate portion 608 of the expandable medical device 600 to the intermediate configuration, the first end portion 604 and the second end portion 606 are deployed to the deployed configuration after release of the first constraining mechanism (e.g., as shown in
In the intermediate configuration, the intermediate portion 608 of the expandable medical device 600 may include a diameter less than a diameter of the intermediate portion 608 of the expandable medical device 600 in the deployed configuration. The diameter of the intermediate portion 608 in the intermediate configuration may be approximately between 40% to 80% less than a diameter of the intermediate portion 608 in the deployed configuration. The second constraining mechanism 602 may constrain the intermediate portion 608 in the intermediate configuration until the second constraining mechanism 602 is released. For example, the second constraining mechanism 602 is configured to release and deploy the intermediate portion 608 of the expandable medical device 600 to the fully deployed configuration. The second constraining mechanism 602 is released in response to a force applied thereto. In certain instances, the force may be a radial force applied within the intermediate portion 608 of the expandable medical device 600. In addition, the force may be applied by an inflatable balloon or other force applied from within the intermediate portion 608 of the expandable medical device 600.
The second constraining mechanism 602 may release, rupture, distend, or otherwise break in response to the force. Further, the second constraining mechanism 602 may be configured to remain coupled to the expandable medical device 600 subsequent to the force being applied thereto with the first constraining mechanism being configured to deploy the expandable medical device 600 and uncouple from the expandable medical device 600 in response thereto. The second constraining mechanism 602 may surround or enclose a circumference of the intermediate portion 608 of the expandable medical device 600. In addition, the second constraining mechanism 602 may be a flexible film (formed from, for example, polytetrafluoroethylene (ePTFE)) and attached (and remain attached to after release of the first constraining mechanism) to one or more portions of the intermediate portion 608 of the expandable medical device 600 via a medical adhesive (e.g., fluorinated ethylene propylene (FEP), a polymer of tetrafluoroethylene, hexafluoropropylene and vinylidene fluoride (THV), and other biocompatible adhesives).
As noted above, the intermediate portion 608 includes a radially expansive force that is greater than a radially expansive force than one or both of the first end portion 604 and the second end portion 606 in the constrained (delivery) configuration. Thus, the second constraining mechanism 602 may be configured to mitigate against premature deployment of the expandable medical device 600. The intermediate portion 608 has a radially expansive force greater than one or both of the first end portion 604 and the second end portion 606 that may force the first constraining mechanism (not shown) to be removed/released from the expandable medical device 600 without a user applying tension to remove the first constraining mechanism. The second constraining mechanism 602 may be configured to lessen expansion of the intermediate portion 608, thereby mitigating against the potential for the intermediate portion 608 to force the first constraining mechanism from the expandable medical device 600 without the user removing the first constraining mechanism.
In addition, the second constraining mechanism 602 may be arranged between the first constraining mechanism (prior to release thereof) and the intermediate portion 608 of the expandable medical device 600. Further, the second constraining mechanism 602 may be arranged within the bounds of the intermediate portion 608 of the expandable medical device 600 as shown in
In certain instances, the intermediate portion 608 of the expandable medical device 600 is constructed to have a tailored radial strength by, for example, varying sine wave amplitude, angle, number of apices per row, number of rows, and/or wire diameter of the elongate elements 610 (or other similar constructions). In addition, the intermediate portion 608 of the expandable medical device 600 includes a radial strength to resist circumferential loading from the surrounding tissue. In certain instances, the radial strength of the intermediate portion 608 of the expandable medical device 600 facilitates remodeling of the tissue external to the intermediate portion 608 to become approximate in size to the outer diameter of the intermediate portion 608. When the expandable medical device 600 (and the other expandable medical devices discussed herein) is implanted to form an anastomosis, the radial strength of the intermediate portion 608 may provide resistance to the hoop force applied by the surrounding tissue. Thus, the expandable medical device 600 substantially maintains an open lumen at a desired dimension.
The expandable medical devices, as discussed herein, may form a connection between two areas. The connection may also be referred to herein as a “shunt,” “passageway,” “shunt passageway,” or “tunnel”. In certain instances, the expandable medical devices discussed herein are configured to be removable after implantation. For example, the expandable medical devices may be implanted and remain in place until the gallbladder and/or its associated ducts are cleared of blockages, after which the device is removed. In another example, the expandable medical devices may remain implanted until the body grows a tissue-anastomosis around the device, and then the device is removed. In other instances, tissue ingrowth into and/or around the device permanently implants the expandable medical device, and the expandable medical device is not removed. The expandable medical devices discussed herein may provide an alternative treatment for patients who are not suitable candidates for other types of treatments (e.g., gallbladder removal surgery) and/or to avoid known complications of other types of treatments (e.g., external biliary drainage).
In certain instances, the elongate elements or framework of the expandable medical devices may be treated in various ways to increase the radiopacity of the expandable medical devices for enhanced radiographic visualization. In some embodiments, the expandable medical devices are at least partially a drawn-filled type of NiTi containing a different material at the core, such as a material with enhanced radiopacity. In some embodiments, the devices include a radiopaque cladding or plating on at least portions of the expandable medical devices. In certain instances, one or more radiopaque markers are attached to the expandable medical devices. In certain instances, the elongate elements and/or other portions of the expandable medical devices provided herein are also visible via ultrasound, and may include portions with enhanced echogenicity.
In addition, the covering material arranged on the expandable medical devices may be generally fluid impermeable. For example, the covering material may be made of a material that inhibits or reduces passage of blood, bile and/or other bodily fluids and materials through the covering material. In certain instances, the covering material has a material composition and configuration that inhibits or prevents tissue ingrowth and/or endothelialization or epithelialization into the covering material. In addition, the covering material may be configured to inhibit or prevent tissue ingrowth and/or endothelialization such that the expandable medical devices may be more readily removed from the patient at a future date. In certain instances, the covering material, or portions thereof, may include a microporous structure that provides a tissue ingrowth scaffold for durable sealing and/or supplemental anchoring strength of the expandable medical devices.
The covering material and the constraining mechanisms may include a fluoropolymer membrane, such as an expanded polytetrafluoroethylene (ePTFE) polymer, polyvinylidene fluoride (PVDF), or polyvinylidene acetate (PVDA). In other instances, the covering material comprises a polyester, a silicone, a urethane, biocompatible polymer(s), polyethylene terephthalate (e.g., Dacron®), bioabsorbable materials, copolymers, or combinations thereof. In addition, the covering material may include a bioabsorbable web. Expanded polytetrafluoroethylene (ePTFE) membranes prepared in accordance with the methods described in U.S. Pat. No. 7,306,729 to Bacino et al., U.S. Pat. No. 3,953,566 to Gore, U.S. Pat. No. 5,476,589 to Bacino, or U.S. Pat. No. 5,183,545 to Branca et al. may be used as the covering material herein. Additionally, expanded modified PTFE and expanded copolymers of PTFE, such as described in U.S. Pat. No. 5,708,044 to Branca; U.S. Pat. No. 6,541,589 to Baillie; U.S. Pat. No. 7,531,611 to Sabol et al.; U.S. Pat. No. 8,637,144 to Ford; and U.S. Pat. No. 9,139,669 to Xu et al. may be used herein. In other embodiments, the bioabsorbable material may also provide an anti-migration feature by promoting attachment between the expandable medical devices and tissue until the bioabsorbable material is absorbed.
The covering material (or portions thereof) may also be modified by one or more chemical or physical processes that enhance one or more properties of the coating. For example, a hydrophilic coating may be applied to the covering material to improve the wettability and echo translucency of the covering. In certain instances, the covering material, or portions thereof, may be modified with chemical moieties that facilitate one or more of endothelial cell attachment, endothelial cell migration, endothelial cell proliferation, and resistance to or promotion of thrombosis. In certain instances, the covering material, or portions thereof, may be modified to resist biofouling. In addition, the covering material, or portions thereof, may be modified with one or more covalently attached drug substances (e.g., heparin, antibiotics, and the like) or impregnated with the one or more drug substances. The drug substances can be released in situ to promote healing, reduce tissue inflammation, reduce or inhibit infections, and to promote various other therapeutic treatments and outcomes. In some embodiments, the drug substance may be, but is not limited to a corticosteroid, a human growth factor, an anti-mitotic agent, an antithrombotic agent, a stem cell material, or dexamethasone sodium phosphate. In addition, a pharmacological agent may be delivered separately from the covering material to the target site to promote tissue healing or tissue growth.
Persons skilled in the art will readily appreciate that various aspects of the present disclosure can be realized by any number of methods and apparatus configured to perform the intended functions. It should also be noted that the accompanying figures referred to herein are not necessarily drawn to scale, but may be exaggerated to illustrate various aspects of the present disclosure, and in that regard, the figures should not be construed as limiting.
This application claims the benefit of Provisional Application No. 62/486,744, filed Apr. 18, 2017, which is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3818511 | Goldberg et al. | Jun 1974 | A |
4119100 | Rickett | Oct 1978 | A |
4338937 | Lerman | Jul 1982 | A |
4381765 | Burton | May 1983 | A |
5224953 | Morgentaler | Jul 1993 | A |
5261898 | Polin et al. | Nov 1993 | A |
5354308 | Simon et al. | Oct 1994 | A |
5562728 | Lazarus et al. | Oct 1996 | A |
5741297 | Simon | Apr 1998 | A |
5755778 | Kleshinski | May 1998 | A |
5797933 | Snow et al. | Aug 1998 | A |
5830222 | Makower | Nov 1998 | A |
5868783 | Tower | Feb 1999 | A |
5945994 | Shimizu et al. | Aug 1999 | A |
5957949 | Leonhardt et al. | Sep 1999 | A |
6007544 | Kim | Dec 1999 | A |
6077291 | Das | Jun 2000 | A |
6120534 | Ruiz | Sep 2000 | A |
6165209 | Patterson et al. | Dec 2000 | A |
6168621 | Vrba | Jan 2001 | B1 |
6171329 | Shaw et al. | Jan 2001 | B1 |
6193734 | Bolduc et al. | Feb 2001 | B1 |
6214029 | Thill et al. | Apr 2001 | B1 |
6217608 | Penn et al. | Apr 2001 | B1 |
6290728 | Phelps et al. | Sep 2001 | B1 |
6315708 | Salmon et al. | Nov 2001 | B1 |
6315792 | Armstrong et al. | Nov 2001 | B1 |
6355052 | Neuss et al. | Mar 2002 | B1 |
6391036 | Berg et al. | May 2002 | B1 |
6391039 | Nicholas et al. | May 2002 | B1 |
6416543 | Hilaire et al. | Jul 2002 | B1 |
6419681 | Vargas et al. | Jul 2002 | B1 |
6432127 | Kim et al. | Aug 2002 | B1 |
6468303 | Amplatz et al. | Oct 2002 | B1 |
6485496 | Suyker et al. | Nov 2002 | B1 |
6485507 | Walak et al. | Nov 2002 | B1 |
6488702 | Besselink | Dec 2002 | B1 |
6579314 | Lombardi et al. | Jun 2003 | B1 |
6585758 | Chouinard et al. | Jul 2003 | B1 |
6616675 | Evard et al. | Sep 2003 | B1 |
6629992 | Bigus et al. | Oct 2003 | B2 |
6666883 | Seguin et al. | Dec 2003 | B1 |
6712836 | Berg et al. | Mar 2004 | B1 |
6863684 | Kim et al. | Mar 2005 | B2 |
6866674 | Galdonik et al. | Mar 2005 | B2 |
6911037 | Gainor et al. | Jun 2005 | B2 |
6945994 | Austin et al. | Sep 2005 | B2 |
6958037 | Ewers et al. | Oct 2005 | B2 |
7022131 | Derowe et al. | Apr 2006 | B1 |
7025777 | Moore | Apr 2006 | B2 |
7029482 | Vargas et al. | Apr 2006 | B1 |
7037344 | Kagan et al. | May 2006 | B2 |
7115136 | Park et al. | Oct 2006 | B2 |
7182771 | Houser et al. | Feb 2007 | B1 |
7223274 | Vargas et al. | May 2007 | B2 |
7252680 | Freitag | Aug 2007 | B2 |
7303569 | Yencho et al. | Dec 2007 | B2 |
7431729 | Chanduszko | Oct 2008 | B2 |
7527644 | Mangiardi et al. | May 2009 | B2 |
7547321 | Silvestri et al. | Jun 2009 | B2 |
7585306 | Abbott et al. | Sep 2009 | B2 |
7608086 | Tanaka et al. | Oct 2009 | B2 |
7632302 | Vreeman et al. | Dec 2009 | B2 |
7780686 | Park et al. | Aug 2010 | B2 |
7828814 | Brenneman et al. | Nov 2010 | B2 |
7892247 | Conston et al. | Feb 2011 | B2 |
7901430 | Matsuura et al. | Mar 2011 | B2 |
8043360 | McNamara et al. | Oct 2011 | B2 |
8109946 | Cahill et al. | Feb 2012 | B2 |
8114125 | Seibold et al. | Feb 2012 | B2 |
8197498 | Coleman et al. | Jun 2012 | B2 |
8257389 | Chanduszko et al. | Sep 2012 | B2 |
8262691 | McGuckin et al. | Sep 2012 | B2 |
8343088 | Bates et al. | Jan 2013 | B2 |
8398676 | Roorda et al. | Mar 2013 | B2 |
8409167 | Roschak | Apr 2013 | B2 |
8425539 | Binmoeller et al. | Apr 2013 | B2 |
8430934 | Das | Apr 2013 | B2 |
8435284 | Eidenschink et al. | May 2013 | B2 |
8454632 | Binmoeller et al. | Jun 2013 | B2 |
8579935 | Devries et al. | Nov 2013 | B2 |
8641747 | Brenneman et al. | Feb 2014 | B2 |
8679171 | Deem et al. | Mar 2014 | B2 |
8728155 | Montorfano et al. | May 2014 | B2 |
8740940 | Maahs et al. | Jun 2014 | B2 |
8864813 | Barr | Oct 2014 | B2 |
8870916 | Ewers et al. | Oct 2014 | B2 |
8992604 | Gross et al. | Mar 2015 | B2 |
9597204 | Benary et al. | Mar 2017 | B2 |
9668853 | Shin | Jun 2017 | B2 |
9782533 | Brenneman et al. | Oct 2017 | B2 |
9993251 | Todd et al. | Jun 2018 | B2 |
10004509 | Todd | Jun 2018 | B2 |
10363040 | Sambandam | Jul 2019 | B2 |
10806458 | Todd | Oct 2020 | B2 |
11439396 | Gore et al. | Sep 2022 | B2 |
20010021872 | Bailey et al. | Sep 2001 | A1 |
20010047180 | Grudem et al. | Nov 2001 | A1 |
20020082627 | Berg et al. | Jun 2002 | A1 |
20020099431 | Armstrong et al. | Jul 2002 | A1 |
20020099437 | Anson et al. | Jul 2002 | A1 |
20020161341 | Stinson | Oct 2002 | A1 |
20020169475 | Gainor et al. | Nov 2002 | A1 |
20020183787 | Wahr et al. | Dec 2002 | A1 |
20030028213 | Thill et al. | Feb 2003 | A1 |
20030032967 | Park et al. | Feb 2003 | A1 |
20030069533 | Kakutani et al. | Apr 2003 | A1 |
20030093096 | McGuckin et al. | May 2003 | A1 |
20030109893 | Margas et al. | Jun 2003 | A1 |
20030120292 | Park et al. | Jun 2003 | A1 |
20030139819 | Beer et al. | Jul 2003 | A1 |
20030144578 | Koster | Jul 2003 | A1 |
20030191482 | Suyker et al. | Oct 2003 | A1 |
20030225421 | Peavey et al. | Dec 2003 | A1 |
20040073242 | Chanduszko | Apr 2004 | A1 |
20040078053 | Berg et al. | Apr 2004 | A1 |
20040092977 | Vargas et al. | May 2004 | A1 |
20040098105 | Stinson et al. | May 2004 | A1 |
20040133236 | Chanduszko | Jul 2004 | A1 |
20040204755 | Robin | Oct 2004 | A1 |
20040211433 | Albright | Oct 2004 | A1 |
20050049675 | Wallace | Mar 2005 | A1 |
20050055082 | Ben Muvhar et al. | Mar 2005 | A1 |
20050070934 | Tanaka et al. | Mar 2005 | A1 |
20050070935 | Ortiz | Mar 2005 | A1 |
20050070957 | Das | Mar 2005 | A1 |
20050149071 | Abbott et al. | Jul 2005 | A1 |
20050154465 | Hodges et al. | Jul 2005 | A1 |
20050228413 | Binmoeller et al. | Oct 2005 | A1 |
20050234509 | Widomski et al. | Oct 2005 | A1 |
20050251201 | Roue et al. | Nov 2005 | A1 |
20050273124 | Chanduszko | Dec 2005 | A1 |
20050288786 | Chanduszko | Dec 2005 | A1 |
20060047337 | Brenneman | Mar 2006 | A1 |
20060052821 | Abbott et al. | Mar 2006 | A1 |
20060106418 | Seibold et al. | May 2006 | A1 |
20060200228 | Penn et al. | Sep 2006 | A1 |
20060217761 | Opolski | Sep 2006 | A1 |
20070055358 | Krolik et al. | Mar 2007 | A1 |
20070073337 | Abbott et al. | Mar 2007 | A1 |
20070123917 | Ortiz et al. | May 2007 | A1 |
20070168014 | Jimenez | Jul 2007 | A1 |
20070244518 | Callaghan | Oct 2007 | A1 |
20070249985 | Brenneman et al. | Oct 2007 | A1 |
20070282430 | Thommen et al. | Dec 2007 | A1 |
20070283552 | Gale et al. | Dec 2007 | A1 |
20080086168 | Cahill | Apr 2008 | A1 |
20080091235 | Sirota | Apr 2008 | A1 |
20080243151 | Binmoeller | Oct 2008 | A1 |
20080262518 | Freudenthal | Oct 2008 | A1 |
20090076541 | Chin et al. | Mar 2009 | A1 |
20090090366 | Cuevas et al. | Apr 2009 | A1 |
20090093873 | Navia | Apr 2009 | A1 |
20090118745 | Paul, Jr. | May 2009 | A1 |
20090143713 | Van Dam | Jun 2009 | A1 |
20090187240 | Clerc et al. | Jul 2009 | A1 |
20090228038 | Amin | Sep 2009 | A1 |
20090281557 | Sander et al. | Nov 2009 | A1 |
20100010520 | Takahashi et al. | Jan 2010 | A1 |
20100023132 | Imran | Jan 2010 | A1 |
20100036401 | Navia | Feb 2010 | A1 |
20100100105 | Bates et al. | Apr 2010 | A1 |
20100106171 | Arepally et al. | Apr 2010 | A1 |
20100114128 | Coleman et al. | May 2010 | A1 |
20100114290 | Rasmussen | May 2010 | A1 |
20100130995 | Yevzlin | May 2010 | A1 |
20100174253 | Cline et al. | Jul 2010 | A1 |
20100234878 | Hruska et al. | Sep 2010 | A1 |
20100268316 | Brenneman et al. | Oct 2010 | A1 |
20100305590 | Holmes et al. | Dec 2010 | A1 |
20110040366 | Goetz et al. | Feb 2011 | A1 |
20110054381 | Van Dam et al. | Mar 2011 | A1 |
20110060398 | Tupil et al. | Mar 2011 | A1 |
20110118765 | Aguirre | May 2011 | A1 |
20110125244 | Roeder | May 2011 | A1 |
20110137410 | Hacohen | Jun 2011 | A1 |
20110213415 | McGuckin et al. | Sep 2011 | A1 |
20110218609 | Chobotov | Sep 2011 | A1 |
20110257461 | Lipperman et al. | Oct 2011 | A1 |
20110257723 | McNamara | Oct 2011 | A1 |
20110301689 | Dorn | Dec 2011 | A1 |
20120065652 | Cully et al. | Mar 2012 | A1 |
20120089216 | Rapaport et al. | Apr 2012 | A1 |
20120130417 | Lepulu et al. | May 2012 | A1 |
20120172927 | Cambell et al. | Jul 2012 | A1 |
20120232505 | Eskaros et al. | Sep 2012 | A1 |
20120241503 | Baxter, III et al. | Sep 2012 | A1 |
20130012969 | Shin | Jan 2013 | A1 |
20130030351 | Belhe | Jan 2013 | A1 |
20130030521 | Nitzan et al. | Jan 2013 | A1 |
20130041451 | Patterson et al. | Feb 2013 | A1 |
20130053784 | Houser et al. | Feb 2013 | A1 |
20130096606 | Bruchman | Apr 2013 | A1 |
20130165967 | Amin et al. | Jun 2013 | A1 |
20130197623 | McHugo | Aug 2013 | A1 |
20130218192 | Erzberger et al. | Aug 2013 | A1 |
20130245742 | Norris | Sep 2013 | A1 |
20130261531 | Gallagher | Oct 2013 | A1 |
20130317546 | Brown | Nov 2013 | A1 |
20140012368 | Sugimoto et al. | Jan 2014 | A1 |
20140031842 | Brenneman et al. | Jan 2014 | A1 |
20140074155 | Rothstein | Mar 2014 | A1 |
20140236064 | Binmoeller et al. | Aug 2014 | A1 |
20140303710 | Zhang et al. | Oct 2014 | A1 |
20140343602 | Cox et al. | Nov 2014 | A1 |
20150005810 | Center | Jan 2015 | A1 |
20150066077 | Akpinar | Mar 2015 | A1 |
20150250630 | Irwin | Sep 2015 | A1 |
20150265437 | Fleury | Sep 2015 | A1 |
20150313595 | Houghton | Nov 2015 | A1 |
20150313598 | Todd et al. | Nov 2015 | A1 |
20150313599 | Johnson | Nov 2015 | A1 |
20160045199 | Mooney | Feb 2016 | A1 |
20160135813 | Johnson | May 2016 | A1 |
20160256169 | Ben-Muvhar | Sep 2016 | A1 |
20170020498 | Blom | Jan 2017 | A1 |
20170105854 | Treacy et al. | Apr 2017 | A1 |
20180221194 | Eskaros et al. | Aug 2018 | A1 |
20180242972 | Todd | Aug 2018 | A1 |
20180250009 | Todd et al. | Sep 2018 | A1 |
20180296809 | Johnson | Oct 2018 | A1 |
20200015823 | Sambandam | Jan 2020 | A1 |
20200146680 | Houghton et al. | May 2020 | A1 |
20210085328 | Todd | Mar 2021 | A1 |
20220257252 | Gore et al. | Aug 2022 | A1 |
20220370071 | Johnson et al. | Nov 2022 | A1 |
Number | Date | Country |
---|---|---|
101374477 | Feb 2009 | CN |
101951983 | Jan 2011 | CN |
102395323 | Mar 2012 | CN |
103209649 | Jul 2013 | CN |
103598902 | Feb 2014 | CN |
104168839 | Nov 2014 | CN |
104244843 | Dec 2014 | CN |
104519838 | Apr 2015 | CN |
106413586 | Feb 2017 | CN |
10148185 | Apr 2003 | DE |
0991375 | Apr 2000 | EP |
1790297 | May 2007 | EP |
1480565 | Dec 2008 | EP |
2543323 | Jan 2013 | EP |
3136982 | Mar 2017 | EP |
3136984 | Mar 2017 | EP |
2409978 | Jul 2005 | GB |
2000-505316 | May 2000 | JP |
2001-501493 | Feb 2001 | JP |
2001520908 | Nov 2001 | JP |
2001-340346 | Dec 2001 | JP |
2003-527939 | Sep 2003 | JP |
2004-049806 | Feb 2004 | JP |
2005-518863 | Jun 2005 | JP |
2005-528181 | Sep 2005 | JP |
2005-534390 | Nov 2005 | JP |
2006-006648 | Jan 2006 | JP |
2007-530128 | Nov 2007 | JP |
2009-508641 | Mar 2009 | JP |
2009518149 | May 2009 | JP |
2010-523209 | Jul 2010 | JP |
2010-528821 | Aug 2010 | JP |
2011-509758 | Mar 2011 | JP |
2011-519709 | Jul 2011 | JP |
2013013715 | Jan 2013 | JP |
2014-503246 | Feb 2014 | JP |
2015-500665 | Jan 2015 | JP |
2021-155586 | Oct 2021 | JP |
2021-192846 | Dec 2021 | JP |
9727898 | Aug 1997 | WO |
9732543 | Sep 1997 | WO |
9802099 | Jan 1998 | WO |
WO-199808462 | Mar 1998 | WO |
WO-199816174 | Apr 1998 | WO |
9858600 | Dec 1998 | WO |
WO-2001072367 | Oct 2001 | WO |
2003028522 | Apr 2003 | WO |
0373944 | Sep 2003 | WO |
2003103476 | Dec 2003 | WO |
2004012603 | Feb 2004 | WO |
2004087236 | Oct 2004 | WO |
2005089655 | Sep 2005 | WO |
2007024964 | Mar 2007 | WO |
2007053243 | May 2007 | WO |
WO-2007100970 | Sep 2007 | WO |
2008157172 | Dec 2008 | WO |
2009082718 | Jul 2009 | WO |
2009091899 | Jul 2009 | WO |
2009109348 | Sep 2009 | WO |
2009140195 | Nov 2009 | WO |
2009146369 | Dec 2009 | WO |
2010129162 | Nov 2010 | WO |
2012034108 | Mar 2012 | WO |
2012067912 | May 2012 | WO |
WO-2012071075 | May 2012 | WO |
WO-2013152891 | Oct 2013 | WO |
2015168506 | Nov 2015 | WO |
2015168507 | Nov 2015 | WO |
2015168508 | Nov 2015 | WO |
WO-2015168501 | Nov 2015 | WO |
WO-2015168504 | Nov 2015 | WO |
Entry |
---|
International Search Report and Written Opinion from PCT/US2018/028120, dated Aug. 21, 2018, 17 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US15/28711, dated Nov. 17, 2016, 11 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US15/28715, dated Nov. 17, 2016, 8 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US15/28717, dated Nov. 17, 2016, 9 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US15/28721, dated Nov. 17, 2016, 8 pages. |
International Search Report and Written Opinion from PCT/US2012/027984, dated Jun. 6, 2012, 11 pages. |
International Search Report and Written Opinion from PCT/US2015/028707, dated Oct. 23, 2015, 19 pages. |
International Search Report and Written Opinion from PCT/US2015/028721, dated Oct. 28, 2015, 13 pages. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US15/28711, dated Feb. 1, 2016, 17 pages. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US15/28715, dated Aug. 25, 2015, 12 pages. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US15/28717, dated Aug. 26, 2015, 13 pages. |
European Search Report from 15721986.6 dated Dec. 12, 2017, 4 pages. |
Extended European Search Report from EP18161679.8, dated Jun. 20, 2018, 7 pages. |
International Search Report and Written Opinion from PCT/2015/028711, completed Jan. 20, 2016, 17 pages. |
International Search Report and Written Opinion from PCT/US2015/028707, completed Oct. 14, 2015, 19 pages. |
International Search Report for PCT/US2016/055255 dated Dec. 20, 2016 and mailed Jan. 20, 2017, 5 pages. |
Number | Date | Country | |
---|---|---|---|
20180296809 A1 | Oct 2018 | US |
Number | Date | Country | |
---|---|---|---|
62486744 | Apr 2017 | US |